**Supplementary Information**

**Suppl. Methods:**

**Preparation and storage of serum and PBMC:** Serum samples were obtained from native venous blood and stored at −20°C until evaluation. Peripheral blood mononuclear cells were prepared from heparinized blood by Ficoll Paque density gradient centrifugation, as previously described (1) and immediately used for flow-cytometric assays and antigen-specific re-stimulation.

**SARS-CoV-2 neutralization assay:** In brief,SARS-CoV-2 neutralization(NT) tests were performed as follows: Vero cells (ATCC CCL-81) sourced from the European Collectionof Authenticated Cell Cultures (84113001) were cultured in TC-Vero medium supplemented with 5% fetal calf serum, L-glutamine(2 mM), nonessential amino acids (1x), sodium pyruvate(1 mM), gentamicin sulfate (100 mg/ml), and sodiumbicarbonate (7.5%). SARS-CoV-2 strain BetaCoV/Germany/Bav-Pat1/2020 was kindly provided by the Institute of Virology atCharité Universitätsmedizin, Berlin, Germany. For the SARS-CoV-2 neutralization assays, samples were serially diluted 1:2 andincubated with 100 tissue culture infectious dose 50% (TCID50) ofSARS-CoV-2 per well. The samples were subsequently appliedonto Vero cells seeded in tissue culture plates and incubated for 5to 7 days, after which the cells were evaluated for the presence of acytopathic effect and the SARS-CoV-2 neutralization titer (NT50),i. e. the reciprocal sample dilution resulting in 50% virus neutralization,was determined using the Spearman-Kärber formulaand reported as 1:X. Cut-off values varied between 1:3 and 1:7.7NT50 between the assay runs, depending on sample-predilutionand level of sample cytotoxicity.

**Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)** obtained from Euroimmune®, Euroimmun Medizinische Labordiagnostik AG (Lübeck, Germany) was carried out according to the manufacturer’s instructions and results were calculated as binding antibody units (BAU)/ml.

**SARS-CoV-2-NeutraLISA surrogate virus neutralization test (sVNT)** obtained from Euroimmune®, Euroimmun Medizinische Labordiagnostik AG (Lübeck, Germany) was carried out according to the manufacturer’s instructions and results were calculated as % inhibition (% inhibition <20 negative; % inhibition ≥20 to <35 borderline; % inhibition ≥35 positive). In brief, wells coated with SARS-CoV-2S1/RBD domain were incubated with soluble ACE2 protein and diluted serum. Neutralizing Abs present in sera inhibit the binding of ACE2 to the S1/RBD proteins on the well surface and are quantified as % inhibition.

**SARS-CoV-2 RBD-specific Abs** were determined using a commercial ELISA for total Abs (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) according to manufacturer’s instructions; results are expressed as ratios (<0.9 negative, 0.9 to 1.1 borderline, >1.1 positive).

**SARS-CoV-2 NCP-specific IgG** were quantified by ELISA (Euroimmune®, Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) carried out according to manufacturer’s instructions; results are expressed as ratios (<0.8 negative, 0.8 to 1.1 borderline, >1.1 positive).

**Detection of S1-specific B memory cells:**To detect SARS-CoV-2 S1-specific B memory cells, biotinylated S1 protein antigen was individually mixed with streptavidin APC and streptavidin BV421 probes. Streptavidin APC-Cy7 was used as a decoy probe to gate out SARS-CoV-2 non-specific streptavidin-binding B cells. The S1 antigen probes and decoy probe were mixed in Brilliant Buffer (BD Bioscience, Cat# 566349) containing 5μM free d-biotin and 3x106 PBMC prepared in U-bottom 96-well plates were stained with 50μL antigen probe cocktail containing 100ng S1 per probe at 4°C for one hour. Then surface staining was performed with directly-labeled monoclonal Abs towards human CD19 (FITC, clone HIB19), human CD27 (PE, clone L128), human CD38 (PerCP-Cy5.5, clone HIT2) and human immunoglobulin D (IgD) (PE-Cy7, clone IA6-2), all BD Bioscience, in Brilliant Buffer at 4°C for 30min. Dead cells were excluded by using Fixable viability dye eFluor-506 (eBioscience, now Thermo Fisher Scientific). Data were acquired on a FACS Canto II flow cytometer by gating on cells with forward/side light scatter properties of lymphocytes and analyzed with FACS Diva 8.0 software.

**PBMC stimulation:** RPMI 1640 supplemented with 2 mM L-glutamine (LonzaTM, BioWhittakerTM, Fisher Scientific, Vienna, Austria) and 5% human AB serum (PAN-Biotech Seraclot, Aidenbach, Germany) was used for antigen-specific re-stimulation of PBMC. For each subject, 5 x 105 freshly isolated PBMC in 190 µl medium were seeded in 96-well plates. Cells were rested overnight and then stimulants PepTivator®SARS-CoV-2 peptide pools for S1-protein and nucleocapside phosphoprotein N (both Miltenyi Biotech B.V. & Co. KG, Bergisch Gladbach, Germany) were added. Lyophilized antigens were reconstituted in sterile water (Cat.-No.: 95284, Merck, Darmstadt, Germany) according to manufacturer’s instructions yielding a stock of 30 nmol of peptide/mL. Working aliquots at 3 nmol/mL in 1x DPBS (GibcoTM Cat.-No.: 14190094, Thermo Fisher Scientific, Vienna, Austria) were stored at -80°C until usage. For stimulation, 10µl of working solutions were added to rested cells (final volume of 200µl with 0.03 nmol of peptide/5 x 105 cells). Negative controls were stimulated with 10µl 1x DPBS, positive controls with 10µl PHA (250µg/mL working solution; 5µ/mL final concentration). Cultures were maintained for 24 h (37°C, 5%CO2, 95% humidity), and thereafter supernatants were taken and stored at -80°C until analysis.

**Cytokine measurements:** Concentrations of interleukin (IL)-2 andinterferon (IFN)-gamma in thawed supernatants were measured with Luminex Human High-Sensitive Cytokine Performance Assays (Bio-techne, Minneapolis, USA) used according to the manufacturer’s instruction on a Luminex® 100/200 System.

**Suppl. Statistical Evaluation:**

Persistence of immunity after infection or vaccination is sometimes life long, such as in measles, however, typically antibody levels decline. It has been shown for vaccination-induced antibodies that decline kinetics are best described by two-component models that are log-linear (additional literature: 2-4). One component starts after the maximum level is reached (a few weeks after the first booster vaccination or after symptoms have resolved in infected individuals) and leads to an initial fast decline. The second component typically starts after a few months and is often very slowly declining (sometimes so slow that a certain level persists lifelong). We have applied such a model for the different antibody measurements.

(1)

Equation (1) describes the antibody level yt at time t months after the baseline time point o as a log linear function of t with a cut point δ (set at 6 months) when the slow component starts to operate (the indicator function x+ takes on zero of x<0 and is =x if x>0).

Parameters ß1 and ß2 were estimated by a General Estimation Equation (GEE) model with an unstructured correlation matrix. In addition, the parameters were estimated for each participant.

**References:**

1. Garner-Spitzer E, Wagner A, Paulke-Korinek M, Kollaritsch H, Heinz FX, Redlberger-Fritz M*, et al.* Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10. *J Immunol* 2013;**191**(5):2426-36 doi 10.4049/jimmunol.1300293.
2. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44(4):446-51.
3. Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723-5727.
4. Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine. 2011;29(14):2607-12.